Skip to main
WVE

WVE Stock Forecast & Price Target

WVE Analyst Ratings

Based on 13 analyst ratings
Buy
Strong Buy 54%
Buy 46%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

WAVE Life Sciences Ltd has demonstrated promising advancements in its clinical programs, particularly with the WVE-007 drug showing a noteworthy 3.2% increase in lean mass, which may support its competitive positioning in the market. The potential to secure a differentiated label through improved functional benefits like stair climbing speed emphasizes the company's strong therapeutic development strategy and its capability to address both rare and prevalent diseases. Furthermore, with revised price targets reflecting positive developments in the economics of its programs and ongoing competitive advantages, WAVE Life Sciences is well-positioned for future growth within the RNA medicine landscape.

Bears say

WAVE Life Sciences Ltd faces a challenging financial landscape, significantly impacted by its inability to raise capital on favorable terms, which could adversely affect stock performance. The lukewarm market reception of its drug candidates, particularly due to their failure to meet market expectations for rapid scale number reductions, raises concerns regarding their commercial viability. Additionally, there are substantial risks associated with the clinical and regulatory success of its lead programs, WVE-004 and WVE-N531, as failures or delays could further diminish revenue prospects and investor confidence.

WVE has been analyzed by 13 analysts, with a consensus rating of Buy. 54% of analysts recommend a Strong Buy, 46% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Wave Life Sciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Wave Life Sciences (WVE) Forecast

Analysts have given WVE a Buy based on their latest research and market trends.

According to 13 analysts, WVE has a Buy consensus rating as of Feb 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $33.62, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $33.62, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Wave Life Sciences (WVE)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.